Výsledky vyhľadávania - "Cristescu, Razvan"

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy Autor Cristescu, Razvan, Mogg, Robin, Ayers, Mark, Albright, Andrew, Murphy, Erin, Yearley, Jennifer, Sher, Xinwei, Liu, Xiao Qiao, Lu, Hongchao, Nebozhyn, Michael, Zhang, Chunsheng, Lunceford, Jared K, Joe, Andrew, Cheng, Jonathan, Webber, Andrea L, Ibrahim, Nageatte, Plimack, Elizabeth R, Ott, Patrick A, Seiwert, Tanguy Y, Ribas, Antoni, McClanahan, Terrill K, Tomassini, Joanne E, Loboda, Andrey, Kaufman, David

“…Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in…”
Zistit podrobnosti o prístupe

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer Autor Kim, Seung Tae, Cristescu, Razvan, Bass, Adam J., Kim, Kyoung-Mee, Odegaard, Justin I., Kim, Kyung, Liu, Xiao Qiao, Sher, Xinwei, Jung, Hun, Lee, Mijin, Lee, Sujin, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Lee, Hyuk, Choi, Mingew, Talasaz, AmirAli, Kang, Peter Soonmo, Cheng, Jonathan, Loboda, Andrey, Lee, Jeeyun, Kang, Won Ki

“…Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic gastric cancer (mGC). With the…”
Získať plný text

An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies Autor O'Neil, Jennifer, Benita, Yair, Feldman, Igor, Chenard, Melissa, Roberts, Brian, Liu, Yaping, Li, Jing, Kral, Astrid, Lejnine, Serguei, Loboda, Andrey, Arthur, William, Cristescu, Razvan, Haines, Brian B, Winter, Christopher, Zhang, Theresa, Bloecher, Andrew, Shumway, Stuart D

“…Combination drug therapy is a widely used paradigm for managing numerous human malignancies. In cancer treatment, additive and/or synergistic drug combinations…”
Zistit podrobnosti o prístupe

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors Autor Cristescu, Razvan, Aurora-Garg, Deepti, Albright, Andrew, Xu, Lei, Liu, Xiao Qiao, Loboda, Andrey, Lang, Lixin, Jin, Fan, Rubin, Eric H, Snyder, Alexandra, Lunceford, Jared

“…BackgroundSeveral studies have evaluated the relationship between tumor mutational burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II…”
Získať plný text

Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab Autor Wei, Bo, Kang, John, Kibukawa, Miho, Arreaza, Gladys, Maguire, Maureen, Chen, Lei, Qiu, Ping, Lang, Lixin, Aurora-Garg, Deepti, Cristescu, Razvan, Levitan, Diane

“…Pembrolizumab is approved for treating patients with unresectable or metastatic solid tumors with high tumor mutational burden (TMB), as assessed by the Food…”
Zistit podrobnosti o prístupe

Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination Autor Fourati, Slim, Cristescu, Razvan, Loboda, Andrey, Talla, Aarthi, Filali, Ali, Railkar, Radha, Schaeffer, Andrea K., Favre, David, Gagnon, Dominic, Peretz, Yoav, Wang, I-Ming, Beals, Chan R., Casimiro, Danilo R., Carayannopoulos, Leonidas N., Sékaly, Rafick-Pierre

“…Aging is associated with hyporesponse to vaccination, whose mechanisms remain unclear. In this study hepatitis B virus (HBV)-naive older adults received three…”
Získať plný text

Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test Autor Cristescu, Razvan, Liu, Xiao Qiao, Arreaza, Gladys, Chen, Cai, Albright, Andrew, Qiu, Ping, Marton, Matthew J.

“…Background: We evaluated the performance of single-nucleotide polymorphism (SNP) genotyping arrays OncoScan (Thermo Fisher Scientific, San Diego, CA) and…”
Získať plný text

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial Autor Hong, Jung Yong, Cho, Hee Jin, Sa, Jason K., Liu, Xiaoqiao, Ha, Sang Yun, Lee, Taehyang, Kim, Hajung, Kang, Wonseok, Sinn, Dong Hyun, Gwak, Geum-Youn, Choi, Moon Seok, Lee, Joon Hyeok, Koh, Kwang Cheol, Paik, Seung Woon, Park, Hee Chul, Kang, Tae Wook, Rhim, Hyunchul, Lee, Su Jin, Cristescu, Razvan, Lee, Jeeyun, Paik, Yong Han, Lim, Ho Yeong

“…Background A limited number of studies have characterized genomic properties of hepatocellular carcinoma (HCC) patients in response to anti-PD-1 immunotherapy…”
Získať plný text

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma Autor Haddad, Robert I, Seiwert, Tanguy Y, Chow, Laura Q M, Gupta, Shilpa, Weiss, Jared, Gluck, Iris, Eder, Joseph P, Burtness, Barbara, Tahara, Makoto, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Albright, Andrew, Mogg, Robin, Ayers, Mark, Huang, Lingkang, Lunceford, Jared, Cristescu, Razvan, Cheng, Jonathan, Mehra, Ranee

“…BackgroundTo characterize genomic determinants of response to pembrolizumab in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the…”
Získať plný text

Somatic mutations render human exome and pathogen DNA more similar Autor Ebrahimzadeh, Ehsan, Engler, Maggie, Tse, David, Cristescu, Razvan, Tchamkerten, Aslan

“…Immunotherapy has recently shown important clinical successes in a substantial number of oncology indications. Additionally, the tumor somatic mutation load…”
Získať plný text

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC Autor Garassino, Marina C., Gadgeel, Shirish, Novello, Silvia, Halmos, Balazs, Felip, Enriqueta, Speranza, Giovanna, Hui, Rina, Garon, Edward B., Horinouchi, Hidehito, Sugawara, Shunichi, Rodriguez-Abreu, Delvys, Reck, Martin, Cristescu, Razvan, Aurora-Garg, Deepti, Loboda, Andrey, Lunceford, Jared, Kobie, Julie, Ayers, Mark, Piperdi, Bilal, Pietanza, M. Catherine, Paz-Ares, Luis

“…We evaluated tissue tumor mutational burden (tTMB) and mutations in STK11, KEAP1, and KRAS as biomarkers for outcomes with pembrolizumab plus platinum-based…”
Získať plný text

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study Autor Dent, Rebecca, Cortés, Javier, Park, Yeon Hee, Muñoz-Couselo, Eva, Kim, Sung-Bae, Sohn, Joohyuk, Im, Seock-Ah, Holgado, Esther, Foukakis, Theodoros, Kümmel, Sherko, Yearley, Jennifer, Wang, Anran, Nebozhyn, Michael, Huang, Lingkang, Cristescu, Razvan, Jelinic, Petar, Karantza, Vassiliki, Schmid, Peter

“…Background The multicohort, open-label, phase 1b KEYNOTE-173 study was conducted to investigate pembrolizumab plus chemotherapy as neoadjuvant therapy for…”
Získať plný text

Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer Autor Baek, Min-Hyun, Chen, Lei, Tekin, Cumhur, Cristescu, Razvan, Jin, Xiao Yang, Shao, Changxia, Ihm, Soo Yeon, Jelinic, Petar, Park, Jeong-Yeol

“…To evaluate the prevalence and prognostic role of programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) in patients with…”
Získať plný text

Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer Autor Park, Song Ee, Park, Kyunghee, Lee, Eunjin, Kim, Ji-Yeon, Ahn, Jin Seok, Im, Young-Hyuck, Lee, Choonghoon, Jung, Hun, Cho, Soo Youn, Park, Woong-Yang, Cristescu, Razvan, Park, Yeon Hee

“…This study explored the clinical implications of tumor mutational burden (TMB) in a well-defined HER2-positive metastatic breast cancer (MBC) patient…”
Získať plný text

Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study Autor Shui, Irene M., Liu, Xiao Qiao, Zhao, Qing, Kim, Seung Tae, Sun, Yuan, Yearley, Jennifer H., Choudhury, Tasmiah, Webber, Andrea L., Krepler, Clemens, Cristescu, Razvan, Lee, Jeeyun

“…BackgroundImmunotherapies targeting programmed cell death-1 (PD-1) and its ligands have improved clinical outcomes for advanced melanoma. However, many tumors…”
Získať plný text

Biomarkers predictive of response to pembrolizumab in head and neck cancer Autor Pfister, David G., Haddad, Robert I., Worden, Francis P., Weiss, Jared, Mehra, Ranee, Chow, Laura Q. M., Liu, Stephen V., Kang, Hyunseok, Saba, Nabil F., Wirth, Lori J., Sukari, Ammar, Massarelli, Erminia, Ayers, Mark, Albright, Andrew, Webber, Andrea L., Mogg, Robin, Lunceford, Jared, Huang, Lingkang, Cristescu, Razvan, Cheng, Jonathan, Seiwert, Tanguy Y., Bauml, Joshua M.

“…Background We performed an integrated biomarker evaluation in pembrolizumab‐treated patients with R/M HNSCC enrolled in KEYNOTE‐012 or KEYNOTE‐055. The…”
Získať plný text

Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial Autor Shitara, Kohei, Di Bartolomeo, Maria, Mandala, Mario, Ryu, Min-Hee, Caglevic, Christian, Olesinski, Tomasz, Chung, Hyun Cheol, Muro, Kei, Goekkurt, Eray, McDermott, Raymond S, Mansoor, Wasat, Wainberg, Zev A, Shih, Chie-Schin, Kobie, Julie, Nebozhyn, Michael, Cristescu, Razvan, Cao, Z Alexander, Loboda, Andrey, Özgüroğlu, Mustafa

“…BackgroundIn the randomized, controlled, phase III KEYNOTE-061 trial, second-line pembrolizumab did not significantly prolong overall survival (OS) versus…”
Získať plný text

Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431] Autor Garassino, Marina C., Gadgeel, Shirish, Novello, Silvia, Halmos, Balazs, Felip, Enriqueta, Speranza, Giovanna, Hui, Rina, Garon, Edward B., Horinouchi, Hidehito, Sugawara, Shunichi, Rodriguez-Abreu, Delvys, Reck, Martin, Cristescu, Razvan, Aurora-Garg, Deepti, Loboda, Andrey, Lunceford, Jared, Kobie, Julie, Ayers, Mark, Piperdi, Bilal, Pietanza, M. Catherine, Paz-Ares, Luis

“…[This corrects the article DOI: 10.1016/j.jtocrr.2022.100431.]…”
Získať plný text

Inhibition of RORγT Skews TCRα Gene Rearrangement and Limits T Cell Repertoire Diversity Autor Guo, Yanxia, MacIsaac, Kenzie D., Chen, Yi, Miller, Richard J., Jain, Renu, Joyce-Shaikh, Barbara, Ferguson, Heidi, Wang, I-Ming, Cristescu, Razvan, Mudgett, John, Engstrom, Laura, Piers, Kyle J., Baltus, Gretchen A., Barr, Kenneth, Zhang, Hongjun, Mehmet, Huseyin, Hegde, Laxminarayan G., Hu, Xiao, Carter, Laura L., Aicher, Thomas D., Glick, Gary, Zaller, Dennis, Hawwari, Abbas, Correll, Craig C., Jones, Dallas C., Cua, Daniel J.

“…Recent studies have elucidated the molecular mechanism of RORγT transcriptional regulation of Th17 differentiation and function. RORγT was initially identified…”
Získať plný text

Prevalence and prognosis of hypoxia‐inducible factor‐2α (HIF‐2α) pathway gene mutations across advanced solid tumors Autor Zhong, Wenjun, Ma, Jiemin, Chen, Cai, Dettman, E. J., Cristescu, Razvan, Naik, Girish S., Jin, Fan, Shao, Changxia

“…Introduction Hypoxia‐inducible factor‐2α (HIF‐2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC,…”
Získať plný text